NOVT Stock Jumps As Earnings Beat Fuels Growth Story

Novanta Inc. stocks have been trading up by 13.72 percent following the most impactful positive sentiment in recent news.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading NOVT

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways For NOVT Traders

Q1 2026 revenue climbed 10% to $257.7M, with 3.1% organic growth, 9% adjusted EPS growth to $0.81, and a 14% rise in adjusted EBITDA for Novanta.
The company topped Q1 expectations on both EPS and revenue, backed by a 37% surge in bookings and a healthy 1.10 book‑to‑bill ratio plus stronger operating cash flow.
Novanta guided Q2 revenue to $259M–$264M, slightly above Street, and Q2 adjusted EPS to $0.81–$0.86, just under consensus at the high end.
Full‑year 2026 revenue guidance was nudged up to $1.04B–$1.055B, while adjusted EPS of $3.50–$3.65 was reaffirmed in line with Wall Street.
CEO Matthijs Glastra sold 6,500 shares for about $845,000 on 2026/04/17 but still holds roughly 111,000 shares, according to an SEC filing.

Live Update At 16:02:38 EDT: On Tuesday, May 12, 2026 Novanta Inc. stock [NASDAQ: NOVT] is trending up by 13.72%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

NOVT has been acting like a textbook earnings breakout. After drifting in the low $120s–$130s through late April, Novanta shares exploded higher following Q1 2026 results, closing at $159.19 on 2026/05/12. That’s a sharp move from $120.89 on 2026/04/29 — roughly a 32% ramp in about two weeks, with the biggest push coming right after the earnings beat.

On the day of the spike, NOVT opened at $149.77, briefly flushed to $145.06, then buyers stepped in hard and drove it as high as $163 before settling near the highs. Intraday 5‑minute candles show steady higher lows all afternoon, signaling strong demand and very little profit‑taking into the close — something momentum traders love to see.

More Breaking News

Fundamentally, Novanta posted Q1 revenue of $257.7M and net income of $21.1M, with EBITDA of $42.36M. Margins are solid for a tech‑leaning industrial: gross margin at 44.4%, EBITDA margin at 17.2%, and EBIT margin at 10.9%. The balance sheet is clean, with low leverage and high liquidity, while operating cash flow of $51.61M and free cash flow of $47.47M back up the earnings quality. For traders, this is a growth name with a rich valuation — a P/E above 90 — but supported by real cash and rising orders.

Why Traders Are Watching NOVT Momentum

NOVT is on watch because Novanta delivered what active traders crave: a clear catalyst, a beat‑and‑raise quarter, and strong tape action. Q1 2026 revenue grew 10% year over year to $257.7M, with 3.1% organic growth. Adjusted EPS climbed 9% to $0.81, and adjusted EBITDA rose 14%. That’s not some hype‑driven story — it’s steady, compounding growth.

What really stands out for Novanta is demand. Bookings jumped 37% year over year and the book‑to‑bill came in at 1.10. That means new orders are running ahead of current shipments, giving NOVT a backlog and visibility into future quarters. Management backed that up with guidance for 6%–8% organic growth in Q2, driven by medical and advanced industrial end markets — areas that typically run on multi‑year projects, not one‑off spikes.

Wall Street got caught leaning too cautious. Consensus called for $0.78 EPS and $253.4M in revenue; Novanta printed $0.81 and $257.7M. That upside surprise, combined with sharply better operating cash flow and negative net debt, explains why NOVT ripped on the chart.

Guidance adds a bit of nuance. For Q2, Novanta sees revenue of $259M–$264M, slightly above the Street, but EPS of $0.81–$0.86, just under consensus at the top end. For the full year, management raised revenue to $1.04B–$1.055B and reaffirmed EPS of $3.50–$3.65. For traders, this says: the top‑line engine is revving, but management is staying conservative on margins. That often keeps a trend more sustainable instead of blowing off in one quarter.

One potential yellow flag is insider selling: CEO Matthijs Glastra sold 6,500 NOVT shares for about $845,000 on 2026/04/17, though he still holds around 111,000 shares. On its own, that looks like normal profit‑taking after a strong run, but experienced traders will keep an eye on future Form 4 filings to see if it turns into a pattern.

Conclusion

NOVT now sits in that sweet spot many growth traders hunt for: strong fundamentals, rising orders, and price confirming the story. Novanta’s Q1 2026 print checked all the key boxes — revenue up 10%, adjusted EPS ahead of consensus, and a 37% jump in bookings with a 1.10 book‑to‑bill. The balance sheet is in good shape, free cash flow is robust, and guidance for both Q2 and the full year supports a steady growth runway.

At the same time, the rich valuation and slightly conservative EPS outlook mean NOVT is not a free ride. Chasing extended candles without a plan is how traders get smoked. The intraday action after earnings shows strong demand, but also big ranges — NOVT moved from $145.06 to $163 in a single session. That’s opportunity and risk, wrapped in one ticker.

For active traders, the setup now is all about levels, volume, and discipline. As Tim Bohen, lead trainer with StocksToTrade says, “A good trade setup checks all the boxes—volume, trend, catalyst. Don’t trade if you’re missing pieces of the puzzle.” If NOVT holds recent support zones and continues to trade heavy volume on green days, the story stays intact. If it cracks hard on light news, that tells you sentiment has flipped.

As Tim Sykes loves to say, “Patterns repeat, but only for traders who are prepared and disciplined enough to act on them.” Treat Novanta and NOVT as a case study: study the earnings, study the chart, and use it to sharpen your trading playbook — not as a signal to blindly buy or sell. This is educational and research content only, not trading advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!